BiotechTube
Phargentis

Phargentis

Lausanne, Switzerland· Est.
phargentis.ch
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

Phargentis is a Swiss virtual biopharma company, founded in 2015, specializing in complex generics and SuperGenerics with a current focus on respiratory diseases. Operating as part of the Chemholding SA group, it leverages a capital-efficient, virtual model by outsourcing development and partnering for commercialization. Its strategy is built on securing API supply from its sister company, Cerbios-Pharma, and licensing out mature products to global pharma partners for distribution.

Respiratory DiseasesOncology

Technology Platform

Development of complex dosage forms and SuperGenerics, leveraging integrated API supply from sister company Cerbios-Pharma for formulation innovation and IP generation.

Funding History

2
Total raised:$17.5M
Series A$15M
Seed$2.5M

Opportunities

The global demand for complex generics and improved versions of existing drugs (SuperGenerics) is growing, driven by cost pressures and the need for better patient outcomes.
The company's focus on technically challenging respiratory formulations and its secure API supply chain create a defensible niche.
Future expansion into oncology offers a significant additional growth avenue.

Risk Factors

The business is heavily reliant on the success of outsourced development and on securing licensing partners for commercialization, creating significant execution and dependency risks.
The core focus on complex formulations, particularly in respiratory diseases, carries high technical and regulatory failure rates.
Competition in the generic and lifecycle management space is intense.

Competitive Landscape

Phargentis competes in the complex generics and SuperGeneric space against other virtual and small biotechs, as well as the generics divisions of large pharmaceutical companies. Its key differentiator is its virtual capital-efficient model and strategic integration with an API manufacturer (Cerbios-Pharma), which provides supply chain security and potential for integrated IP development.

More companies in Switzerland →